SCHEMBL5544161

SCHEMBL5544161

[CH2]CCCN1CCN(C(=O)OCc2cccc(OC(F)(F)F)c2)CC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.54
FNTB P49356 1/20 0.54
PGGT1B P53609 1/20 0.54
HRH2 P25021 2/20 0.51
HRH1 P35367 2/20 0.51
CHRM4 P08173 2/20 0.48
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MGLL Q99685 1/20 0.43
SIGMAR1 Q99720 3/20 0.42
CARM1 Q86X55 2/20 0.42
PRMT6 Q96LA8 2/20 0.42
ACHE P22303 1/20 0.42
FFAR4 Q5NUL3 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
HTR2A P28223 1/20 0.41
HTR7 P34969 1/20 0.41
OPRM1 P35372 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5535289 0.97 FNTA (0.53) FNTAFNTBPGGT1BHRH2HRH1
SCHEMBL5542157 0.95 FNTA (0.56) FNTAFNTBPGGT1BHRH2HRH1
SCHEMBL27610387 0.90 HRH2 (0.54) FNTAFNTBPGGT1BHRH2HRH1
SCHEMBL5545983 0.89 FNTA (0.54) FNTAFNTBPGGT1BHRH2HRH1
SCHEMBL5545989 0.89 FNTA (0.52) FNTAFNTBPGGT1BHRH2HRH1
SCHEMBL5541797 0.88 HRH2 (0.59) FNTAFNTBPGGT1BHRH2HRH1
SCHEMBL5539203 0.88 FNTA (0.53) FNTAFNTBPGGT1BHRH2HRH1
SCHEMBL5539207 0.88 FNTA (0.51) FNTAFNTBPGGT1BHRH2HRH1
SCHEMBL5537935 0.85 HRH2 (0.58) FNTAFNTBPGGT1BHRH2HRH1
SCHEMBL5540076 0.85 KMT2A (0.49) ALDH1A1LMNASIGMAR1CARM1PRMT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 FNTA 2864/4885FNTB 286/4885PGGT1B 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.